Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Hepatobiliary cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
RLY-4008-101A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors | |
|---|---|
| Local Project Reference: | 141772 |
| Principal Investigator: | Prof. John Bridgewater |
| Drug Class/ Treatment: | RLY-4008 (FGFR2 Inhibitor) |
| Patient Population: | Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 Fusion Unresectable or Metastatic Solid Tumours with FGFR2 Fusion, Amplification or Mutation |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
